Abstract
Cerebellar atrophy (CA) is a frequent finding in patients with chronic epilepsy. To find out whether the existence of CA has an influence on the tolerance of high-dose monotherapy with carbamazepine, we compared the lowest individual toxic serum levels in patients with complex focal seizures, with CA (n = 27) and without CA (n = 20) in computerized tomography (CT). There was no statistical difference between the groups, even after separating patients with mild CA (n = 20) from those with more severe damage (n = 7). In addition, other clinical, EEG and CT data also seemed to have no influence on the individual toxic threshold serum levels of carbamazepine.
MeSH terms
-
Adolescent
-
Adult
-
Atrophy
-
Carbamazepine / administration & dosage
-
Carbamazepine / adverse effects*
-
Carbamazepine / pharmacokinetics
-
Cerebellar Ataxia / chemically induced
-
Cerebellar Ataxia / physiopathology
-
Cerebellum / drug effects*
-
Cerebellum / pathology
-
Dose-Response Relationship, Drug
-
Electroencephalography / drug effects
-
Epilepsies, Partial / drug therapy*
-
Epilepsies, Partial / physiopathology
-
Epilepsy, Tonic-Clonic / drug therapy*
-
Epilepsy, Tonic-Clonic / physiopathology
-
Evoked Potentials / drug effects
-
Evoked Potentials / physiology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neurologic Examination / drug effects
-
Nystagmus, Pathologic / chemically induced
-
Nystagmus, Pathologic / physiopathology
-
Retrospective Studies
-
Tomography, X-Ray Computed